380 related articles for article (PubMed ID: 37947195)
21. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST
Drug Discov Today; 2023 Dec; 28(12):103818. PubMed ID: 37925136
[TBL] [Abstract][Full Text] [Related]
22. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
Barnett BS; Parker SE; Weleff J
Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
[TBL] [Abstract][Full Text] [Related]
23. Molecular insights into psychedelic drug action.
Slocum ST; DiBerto JF; Roth BL
J Neurochem; 2022 Jul; 162(1):24-38. PubMed ID: 34797943
[TBL] [Abstract][Full Text] [Related]
24. Psychedelics and mental health: a population study.
Krebs TS; Johansen PØ
PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
[TBL] [Abstract][Full Text] [Related]
25. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
[TBL] [Abstract][Full Text] [Related]
26. Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies.
Weleff J; Akiki TJ; Barnett BS
J Psychoactive Drugs; 2023; 55(4):434-444. PubMed ID: 36218281
[TBL] [Abstract][Full Text] [Related]
27. The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics.
Wilkes R; Roberts DM; Liknaitzky P; Brett J
Clin Toxicol (Phila); 2024 Apr; 62(4):242-247. PubMed ID: 38753585
[TBL] [Abstract][Full Text] [Related]
28. Next generation antidepressants with novel mechanisms for treatment resistant depression.
Chen MH; Tu PC; Su TP
Prog Brain Res; 2023; 278():149-168. PubMed ID: 37414491
[TBL] [Abstract][Full Text] [Related]
29. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
Dos Santos RG; Hallak JE; Baker G; Dursun S
J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
[TBL] [Abstract][Full Text] [Related]
30. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
[TBL] [Abstract][Full Text] [Related]
31. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
Pearson C; Siegel J; Gold JA
J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
[TBL] [Abstract][Full Text] [Related]
32. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL
Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790
[TBL] [Abstract][Full Text] [Related]
33. Psychedelic drugs for psychiatric disorders.
da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
[TBL] [Abstract][Full Text] [Related]
34. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular safety of psychedelic medicine: current status and future directions.
Wsół A
Pharmacol Rep; 2023 Dec; 75(6):1362-1380. PubMed ID: 37874530
[TBL] [Abstract][Full Text] [Related]
36. How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.
van den Berg M; Magaraggia I; Schreiber R; Hillhouse TM; Porter JH
Psychopharmacology (Berl); 2022 Jun; 239(6):1853-1879. PubMed ID: 35348806
[TBL] [Abstract][Full Text] [Related]
37. Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters.
Jahanabadi S; Amiri S; Karkeh-Abadi M; Razmi A
Fitoterapia; 2023 Sep; 169():105620. PubMed ID: 37490982
[TBL] [Abstract][Full Text] [Related]
38. Assessment of the acute subjective psychedelic experience: A review of patient-reported outcome measures in clinical research on classical psychedelics.
Hovmand OR; Poulsen ED; Arnfred S
J Psychopharmacol; 2024 Jan; 38(1):19-32. PubMed ID: 37969069
[TBL] [Abstract][Full Text] [Related]
39. Psychedelic medicines for mood disorders: current evidence and clinical considerations.
Sarris J; Pinzon Rubiano D; Day K; Galvão-Coelho NL; Perkins D
Curr Opin Psychiatry; 2022 Jan; 35(1):22-29. PubMed ID: 34855694
[TBL] [Abstract][Full Text] [Related]
40. Registered clinical studies investigating psychedelic drugs for psychiatric disorders.
Siegel AN; Meshkat S; Benitah K; Lipsitz O; Gill H; Lui LMW; Teopiz KM; McIntyre RS; Rosenblat JD
J Psychiatr Res; 2021 Jul; 139():71-81. PubMed ID: 34048997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]